Loading...
•
Dec 31, 2020
Pliant Therapeutics Q4 2020 Earnings Report
Pliant Therapeutics reported fourth quarter and full year 2020 financial results, and provided a corporate update.
Key Takeaways
Pliant Therapeutics reported a net loss of $19.0 million for the fourth quarter of 2020, compared to a net income of $42.2 million for the prior-year quarter, due to a decrease in related party revenue. Research and development expenses increased to $17.9 million, and general and administrative expenses were $5.6 million. The company had cash, cash equivalents, and short-term investments of $276.9 million as of December 31, 2020.
PLN-74809 Phase 2a PET imaging trial resumed, with preliminary data expected in the first half 2021.
PLN-74809 Phase 2a INTEGRIS trials in IPF and PSC gained momentum in the fourth quarter and are currently on track to complete enrollment by the end of 2021 and the first half of 2022, respectively.
IND open for development of a PET tracer of the protein integrin αvβ1.
Successful completion of PLN-1474 Phase 1 trial and transfer of PLN-1474 to Novartis.
Forward Guidance
Pliant believes it has sufficient funds to meet its operating and capital requirements into 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...